ArticleBlood advances2022
Analysis of racial and ethnic disparities in multiple myeloma US FDA drug approval trials.
Article in Blood advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed.
- Genomic Features Do Not Account for Differences in Multiple Myeloma Risk by Ancestry.Blood cancer discovery · 2026Article
- Overcoming Trial Exclusion: A Multicenter Analysis of Hemodialysis Multiple Myeloma Patients Who Underwent BCMA-Directed CAR-T Therapy.Current oncology (Toronto, Ont.) · 2026Article
- Representation of Women, Older Adults, and Racial and Ethnic Minoritized Patients in Pivotal Trials for US Food and Drug Administration Novel Oncology Therapeutic Approvals, 2012-2021: Bright Spot Trials and Trends Over Time.JCO oncology practice · 2026Article
- The invisible divide: the impact of racial and geographic disparities on multiple myeloma outcomes - insights from a single-site study.Haematologica · 2026Article
- Multiple myeloma risk linked to DNA damage response genes.Journal of hematology & oncology · 2026Article
- Oncologists' Perspectives on Oncology Stewardship: A Focus Group Exploration in a Statewide Quality Improvement Consortium.Cancer management and research · 2026Article
- Article
- Reporting and representation of race and ethnicity data in phase III clinical trials for hematological malignancies.Future science OA · 2025Article
- "First, Trust Needs to Develop": Hematologists' Perspectives on Factors Influencing Black Persons' Participation in Clinical Trials.Journal of racial and ethnic health disparities · 2025Article
- Quality of Life Among Polish Patients with Multiple Myeloma: A Cross-Sectional Study.Medical science monitor : international medical journal of experimental and clinical research · 2025Article
- Trends in multiple myeloma and cardiovascular disease-related mortality among older adults in the United States, 1999 to 2023: a CDC wonder database analysis.Annals of medicine and surgery (2012) · 2025Review
- Monoclonal Gammopathies in Africa.Clinical lymphoma, myeloma & leukemia · 2025Review
- Temporal patterns in US population-based patient survival among adults treated with chemotherapy and/or immunotherapy for multiple myeloma, 2000-2020.British journal of haematology · 2025Article
- Social determinants of health and their impact on frontline treatment patterns among Medicare Advantage members with newly diagnosed multiple myeloma.Journal of managed care & specialty pharmacy · 2025Article
- Impact of Global Enrollment on Race, Ethnicity, and Age Representation in Pivotal Gynecologic Cancer Trials Leading to US Food and Drug Administration Drug Approvals.JCO global oncology · 2025Article
- Paradigm shift in age of multiple myeloma patients: a study from a tertiary care government oncology hospital in Pakistan.BMC research notes · 2025Article
- Ancestral Differences in Anticancer Treatment Efficacy and Their Underlying Genomic and Molecular Alterations.Cancer discovery · 2025Article
- Association of age, race, and ethnicity with access, response, and toxicities from CAR-T therapy in children and adults with B-cell malignancies: a review.Journal for immunotherapy of cancer · 2025Review
- Comparison of Laboratory Data at Initial Diagnosis of Multiple Myeloma Between Black Africans, African Americans and White patients.Clinical lymphoma, myeloma & leukemia · 2024Article
- The American Society of Hematology Health Equity Compendium: examining health equity across the Blood journals.Blood advances · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
African Americans (AAs) have a higher incidence of multiple myeloma (MM) than White patients. Mortality is also higher in AAs compared with White patients. AAs more commonly have immunoglobulin H translocations t(11;14) and t(14;16) compared with White patients. We sought to characterize the demographic representation in MM clinical trials and evaluate outcomes based on race and ethnicity. We conducted a pooled analysis of all trials submitted to the US Food and Drug Administration (FDA) to support approval of a MM therapeutic between 2006 and 2019. Demographic characteristics were analyzed descriptively. An age-adjusted stratified Cox regression model was used to evaluate the relationship between time-to-event outcomes and race and ethnicity. Nineteen global trials comprising 10 157 patients were pooled. White, Asian, and Black patients comprised 84%, 7%, and 4% of the dataset, respectively; Hispanic patients comprised 4%. The age-adjusted overall survival hazard ratio (HR) for Black compared with White patients was 0.89 (95% confidence interval [CI], 0.75-1.05). The age-adjusted HR for US Black vs US White patients was 0.82 (95% CI, 0.66-1.02). For rest-of-world (RoW) Black vs RoW White patients, the HR was 1.31 (95% CI, 0.97-1.77). Black and Hispanic patients were underrepresented in the trials supporting FDA approval of MM drugs. Black patients were primarily enrolled in the United States. Outcomes in US patients were more favorable compared with those in patients in the RoW. Given the higher incidence of MM in AAs and the different disease characteristics, efforts should be made to improve representation of AAs in MM clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.